Penserra Capital Management LLC Acquires New Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Penserra Capital Management LLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,695 shares of the biotechnology company's stock, valued at approximately $420,000.

Several other institutional investors have also modified their holdings of the company. Jones Financial Companies Lllp boosted its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Ascendis Pharma A/S by 32.9% during the 4th quarter. Assetmark Inc. now owns 2,942 shares of the biotechnology company's stock valued at $405,000 after acquiring an additional 728 shares in the last quarter. Atria Investments Inc lifted its holdings in shares of Ascendis Pharma A/S by 19.2% during the 4th quarter. Atria Investments Inc now owns 2,436 shares of the biotechnology company's stock valued at $335,000 after acquiring an additional 393 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth $1,725,000. Finally, HighTower Advisors LLC purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth $484,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Citigroup boosted their price objective on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research report on Friday. Oppenheimer restated an "outperform" rating and issued a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Wedbush upped their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Finally, Royal Bank Of Canada upped their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $223.07.

Ascendis Pharma A/S Stock Performance

ASND traded down $0.07 during mid-day trading on Monday, reaching $174.89. 320,449 shares of the stock were exchanged, compared to its average volume of 505,376. The company has a 50 day moving average price of $168.27 and a two-hundred day moving average price of $153.60. The stock has a market capitalization of $10.69 billion, a PE ratio of -27.85 and a beta of 0.38. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.